Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT

Bone Marrow Transplant. 2008 Aug;42(4):227-40. doi: 10.1038/bmt.2008.162. Epub 2008 Jun 30.

Abstract

These recommendations were prepared by the European Conference on Infections in Leukaemia following a predefined methodology. Literature searches were made to identify studies pertinent to management of CMV, HHV-6, -7 and -8 infections. For CMV, 76 studies were reviewed: 72 published and 4 presented as abstracts. Twenty-nine of these studies were prospective randomized trials. For the other herpesviruses, HHV-6, -7 and -8, no randomized controlled trial has been performed, although data from some studies with other primary endpoints have been used to assess the management of HHV-6 infection. Works presented only as abstracts were used to a very limited extent. The quality of evidence and level of recommendation were graded according to the Center for Disease Control (CDC) criteria.

Publication types

  • Practice Guideline

MeSH terms

  • Cytomegalovirus Infections / diagnosis
  • Cytomegalovirus Infections / prevention & control
  • Cytomegalovirus Infections / therapy*
  • Hematologic Neoplasms / therapy
  • Hematologic Neoplasms / virology*
  • Herpesvirus 6, Human*
  • Herpesvirus 7, Human*
  • Herpesvirus 8, Human*
  • Roseolovirus Infections / diagnosis
  • Roseolovirus Infections / prevention & control
  • Roseolovirus Infections / therapy*
  • Sarcoma, Kaposi / diagnosis*
  • Stem Cell Transplantation* / adverse effects